Stocks and Investing Stocks and Investing
Tue, March 8, 2022
Mon, March 7, 2022

David Lebowitz Maintained (ASND) at Buy with Decreased Target to $180 on, Mar 7th, 2022


Published on 2024-10-27 19:59:05 - WOPRAI, David Lebowitz
  Print publication without navigation


David Lebowitz of Morgan Stanley, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Decreased Target from $197 to $180 on, Mar 7th, 2022.

David has made no other calls on ASND in the last 4 months.



There are 6 other peers that have a rating on ASND. Out of the 6 peers that are also analyzing ASND, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Yaron Werber of "Cowen & Co." Initiated at Hold and Held Target at $136 on, Thursday, January 6th, 2022


These are the ratings of the 5 analyists that currently disagree with David


  • Derek Archila of "Wells Fargo" Maintained at Buy with Decreased Target to $170 on, Thursday, March 3rd, 2022
  • Liana Moussatos of "Wedbush" Maintained at Buy with Decreased Target to $117 on, Thursday, March 3rd, 2022
  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $188 on, Thursday, March 3rd, 2022
  • Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $170 on, Monday, February 14th, 2022
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $190 on, Monday, November 15th, 2021
Contributing Sources